VP6: A candidate rotavirus vaccine.

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Rotavirus is a leading cause of severe diarrheal disease in infants worldwide.
• Current rotavirus vaccines have limitations, necessitating the development of improved vaccine candidates.
• The VP6 protein is a major structural component of the rotavirus particle and a target for vaccine development.

Purpose of the Study:

• To evaluate the efficacy of a nonliving rotavirus vaccine candidate based on the VP6 protein.
• To assess the protective immune response induced by intranasal administration of MBP::VP6 with an adjuvant in a mouse model.

Main Methods:

• The VP6 protein was expressed as a chimera with maltose binding protein (MBP::VP6).
• Mice were immunized intranasally with MBP::VP6 and an adjuvant, then challenged with rotavirus.
• Protection was assessed by measuring fecal shedding of rotavirus and analyzing lymphocyte populations.

Main Results:

• Intranasal vaccination with MBP::VP6 and adjuvant conferred nearly 100% protection against rotavirus fecal shedding in mice.
• Protection was dose-dependent, long-lasting (at least 1 year), effective across mouse strains, and achievable via oral or intrarectal routes.
• Immunity was mediated solely by CD4(+) T cells, distinguishing it from live rotavirus vaccines.

Conclusions:

• The nonliving MBP::VP6 vaccine candidate, when coadministered with an adjuvant, demonstrates potent and durable protection against rotavirus infection in mice.
• This VP6-based vaccine elicits a T-cell-dependent immune response, offering a potential alternative to live rotavirus vaccines.
• Further investigation into VP6-derived vaccines for human use is warranted, potentially representing a second-generation rotavirus vaccine.